A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
Condition: Healthy Interventions: Biological: Ad26.RSV.preF; Biological: Fluarix; Biological: Placebo Sponsor: Janssen Vaccines & Prevention B.V. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenoviruses | Influenza | Influenza Vaccine | Research | Respiratory Medicine | Study | Vaccines